Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 M

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • Cancer Words Matter

    MPN NEWS | February 20, 2024

    Cancer is such a powerful word that it is often referred to as “The Big C” and comes with a loaded associated vocabulary, including words that can have both empowering or disturbing triggers, depending on the individual hearing it.   Not many people go through life without being touched by cancer in some way. This means… Read More »Cancer Words Matter


    Cardiovascular Risk and MPNs

    MPN NEWS | February 20, 2024

    While cardiovascular events often accompany MPNs and contribute significantly to morbidity and mortality, the reasons remained unclear until research offered some insight in recent years.  Greater understanding about why and how blood cancers have connections to cardiovascular complications lays the groundwork to using this information to better assess and manage risk factors in MPN patients,… Read More »Cardiovascular Risk and MPNs


    How MPNs Progress to AML and How to Stop It

    MPN NEWS | February 20, 2024

    Thrive Award Spotlight: John Crispino, St. Jude Children’s Research HospitalCo-PI – Ayalew Tefferi, Mayo Clinic, MN Aberrant Megakaryopoiesis in the MPNs According to Leukemia & Lymphoma Society, although MPN patients can be stable for decades, they face a significant risk of having their disease advance to a more immediately life-threatening blood cancer, acute myeloid leukemia… Read More »How MPNs Progress to AML and How to Stop It

  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With an investment today, you can accelerate research for better outcomes.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.


    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    “Under the Microscope”